Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
Clinical trial NCT06849167 · RECRUITING
Trial details
- NCT number
- NCT06849167
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2029-03-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.